Presentation is loading. Please wait.

Presentation is loading. Please wait.

Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions  Chelsea.

Published byReginald Lee Modified over 6 years ago

Similar presentations

Presentation on theme: "Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions  Chelsea."— Presentation transcript:

1 Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions  Chelsea C. Pinnix, MD, PhD, Therese Y. Andraos, MD, Bouthaina Dabaja, MD, Sarah Milgrom, MD, Grace Smith, MD, PhD, Dai Chihara, MD, PhD, Andrea Ng, MD, Luis E. Fayad, MD, Yasuhiro Oki, MD, Sattva Neelapu, MD, Jason Westin, MD, M. Alma Rodriguez, MD, Loretta J. Nastoupil, MD  Advances in Radiation Oncology  Volume 2, Issue 3, Pages (July 2017) DOI: /j.adro Copyright © 2017 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

2 Figure 1 Patient cohort selection.
Advances in Radiation Oncology 2017 2, DOI: ( /j.adro ) Copyright © 2017 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

3 Figure 2 Outcomes among 131 older elderly patients who were treated for stage I-IV diffuse large B-cell lymphoma. (A) Disease-free survival, (B) progression-free survival, and (C) overall survival. Advances in Radiation Oncology 2017 2, DOI: ( /j.adro ) Copyright © 2017 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

4 Figure 3 Outcomes among patients with early stage disease who were treated with abbreviated chemotherapy (3-4 cycles) and radiation therapy versus chemotherapy alone (6-8 cycles). (A) local control, (B) disease-free survival, (C) progression-free survival, and (D) overall survival. Advances in Radiation Oncology 2017 2, DOI: ( /j.adro ) Copyright © 2017 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

5 Figure 4 Outcomes among patients with advanced-stage bulky disease according to receipt of radiation therapy. (A) Local control, (B) disease-free survival, (C) progression-free survival, and (D) overall survival. Advances in Radiation Oncology 2017 2, DOI: ( /j.adro ) Copyright © 2017 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

6 Figure 5 Incidence of Common Terminology Criteria for Adverse Events grade 1 or higher hematologic toxicity according to cycle of chemotherapy among patients with early-stage disease who were treated with 6 to 8 cycles of chemotherapy (n = 17). (A) Anemia, (B) thrombocytopenia, (C) neutropenia, and (D) chemotherapy dose reduction or delay. Advances in Radiation Oncology 2017 2, DOI: ( /j.adro ) Copyright © 2017 The Authors on behalf of the American Society for Radiation Oncology Terms and Conditions

Download ppt "Diffuse large B-cell lymphoma in very elderly patients over 80 years old: Incorporating consolidative radiation therapy into management decisions  Chelsea."

Similar presentations

Neutron radiation therapy for advanced thyroid cancers Tobias R. Chapman, MD, George E. Laramore, PhD, MD, Stephen R. Bowen, PhD, Peter F. Orio, DO, MS.

Neutron radiation therapy for advanced thyroid cancers Tobias R. Chapman, MD, George E. Laramore, PhD, MD, Stephen R. Bowen, PhD, Peter F. Orio, DO, MS.
Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial  K. Ranh Voong, MD MPH, Lincy S. Lal, PhD, Deborah.

Long-term economic value of hypofractionated prostate radiation: Secondary analysis of a randomized trial  K. Ranh Voong, MD MPH, Lincy S. Lal, PhD, Deborah.
Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment.

Single-Institution Experience in the Treatment of Primary Mediastinal B Cell Lymphoma Treated With Immunochemotherapy in the Setting of Response Assessment.
Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes  Stuart E. Samuels, MD, PhD, Matthew.

Neoadjuvant twice daily chemoradiotherapy for esophageal cancer: Treatment-related mortality and long-term outcomes  Stuart E. Samuels, MD, PhD, Matthew.
Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer  Victor E. Chen, BS, Erin.

Pathologic response after neoadjuvant chemotherapy predicts locoregional control in patients with triple negative breast cancer  Victor E. Chen, BS, Erin.
Su K. Metcalfe, MD, MPH, Michael T

Su K. Metcalfe, MD, MPH, Michael T
John Boyle, MD, Brad Ackerson, MD, Lin Gu, MS, Chris R. Kelsey, MD 

John Boyle, MD, Brad Ackerson, MD, Lin Gu, MS, Chris R. Kelsey, MD 
The Use of Hormone Therapy Alone Versus Hormone Therapy and Radiation Therapy for Breast Cancer in Elderly Women: A Population-Based Study  Alan M. Nichol,

The Use of Hormone Therapy Alone Versus Hormone Therapy and Radiation Therapy for Breast Cancer in Elderly Women: A Population-Based Study  Alan M. Nichol,
Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports  Daniel K. Ebner, BS, Tadashi Kamada, MD, PhD,

Abscopal effect in recurrent colorectal cancer treated with carbon-ion radiation therapy: 2 case reports  Daniel K. Ebner, BS, Tadashi Kamada, MD, PhD,
Incorporating big data into treatment plan evaluation: Development of statistical DVH metrics and visualization dashboards  Charles S. Mayo, PhD, John.

Incorporating big data into treatment plan evaluation: Development of statistical DVH metrics and visualization dashboards  Charles S. Mayo, PhD, John.
Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity  Sarah J. Stephens, MD, Samantha Thomas, MB,

Myeloablative conditioning with total body irradiation for AML: Balancing survival and pulmonary toxicity  Sarah J. Stephens, MD, Samantha Thomas, MB,
Efficacy and toxicity of rectal cancer reirradiation using IMRT for patients who have received prior pelvic radiation therapy  Fady F. Youssef, MS, Parag.

Efficacy and toxicity of rectal cancer reirradiation using IMRT for patients who have received prior pelvic radiation therapy  Fady F. Youssef, MS, Parag.
Dosimetric analysis of varying cord planning organ at risk volume in spine stereotactic body radiation therapy  Dawn Owen, MD, PhD, Charles S. Mayo, PhD,

Dosimetric analysis of varying cord planning organ at risk volume in spine stereotactic body radiation therapy  Dawn Owen, MD, PhD, Charles S. Mayo, PhD,
Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey  Lazzaro Repetto  Critical.

Incidence and clinical impact of chemotherapy induced myelotoxicity in cancer patients: An observational retrospective survey  Lazzaro Repetto  Critical.
Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial  Susanne M.

Using low-dose radiation to potentiate the effect of induction chemotherapy in head and neck cancer: Results of a prospective phase 2 trial  Susanne M.
A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy  William.

A phase 2 trial of salvage radiation and concurrent weekly docetaxel after a rising prostate-specific antigen level after radical prostatectomy  William.
Martin Dreyling, MD, PhD  Seminars in Hematology 

Martin Dreyling, MD, PhD  Seminars in Hematology 
Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.

Differences in Primary Care Clinicians' Approach to Non-small Cell Lung Cancer Patients Compared with Breast Cancer  Timothy R. Wassenaar, MD, Jens C.
Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and.

Long-term outcomes of dose-escalated intensity modulated radiation therapy alone without androgen deprivation therapy for patients with intermediate and.
Tijana Skrepnik, MD, Silvija Gottesman, MD, Baldassarre Stea, MD, PhD 

Tijana Skrepnik, MD, Silvija Gottesman, MD, Baldassarre Stea, MD, PhD 

Similar presentations

Ads by Google